Inmune Bio CFO buys $49,000 in company shares by Investing.com

In a recent transaction, David J. Moss, CFO of Inmune Bio, Inc. (NASDAQ: ), a biologics company, increased its stake in the company. On September 12, 2024, Moss purchased 7,690 shares of Inmune Bio common stock at a price of $6.375 per share, for a total investment of $49,023.

This acquisition demonstrates a strong vote of confidence from Moss in the future of Immune Bio. Following the transaction, the chief financial officer now owns a total of 1,275,869 shares of the company’s common stock directly. The acquisition aligns with the company’s ongoing efforts to advance its position in the biologics sector.

In addition, Moss also purchased the same number of stock warrants, which give him the right to purchase additional shares at a future date. The warrants have an exercise price of $6.40 each and are exercisable beginning on March 16, 2025, with an expiration date of March 16, 2030. The terms of the warrants include provisions for an extended exercise period in certain circumstances related to prohibition of insider trading.

The transactions were part of a registered direct offering, according to SEC filing footnotes, with a total purchase price of $13,000,000 for the combined shares and warrants. This strategic move by Moss may indicate his expectations for potential growth or a favorable outlook for Immune Bio, as the purchase of both shares and warrants suggests a long-term commitment to the company’s success.

Investors often monitor insider trades like these for information about how company executives view the stock’s valuation and outlook. Moss’s recent investments have certainly provided such insights, showing a strengthened belief in the company’s direction and potential.

In other recent news, INmun Bio Inc. raised approximately $13 million in gross proceeds from a registered direct offering of common stock and corresponding warrants involving both new and existing institutional investors and company insiders. The anticipated closing date of the offering is on or about September 16, 2024, subject to customary closing conditions. The proceeds are intended for working capital and general corporate purposes, with AGP/Alliance Global Partners (NYSE: ) as the sole placement agent.

Additionally, Scotiabank initiated coverage on INmune Bio shares with a Sector Outperform rating, highlighting the potential of the company’s lead drug candidate, XPro, currently in clinical development for the treatment of Alzheimer’s disease. The company is expected to release top-line results from a six-month Phase 2 study of XPro in early Alzheimer’s patients in the second quarter of 2025.

In addition, INmune Bio reported significant progress in its memory-like natural killer cell oncology platform INKmune and its ongoing Phase II Alzheimer’s study during its Q2 2024 earnings call. Interim analysis of XPro’s Phase II trial in early Alzheimer’s showed promising results, and the company raised approximately $14.5 million in gross proceeds from the equity offerings, securing sufficient funds for operations through 2025. These recent developments underscore INmune Bio’s commitment to to advance. clinical trials and bringing innovative treatments to market.

InvestingPro Insights

As David J. Moss, CFO of Inmune Bio, increases his stake in the company, investors are eager to understand the financial health and market performance of Inmune Bio, Inc. (NASDAQ:INMB). Conformable InvestingPro dataInmune Bio currently has a market capitalization of $105.72 million. The company’s shares have been experiencing significant volatility, with the price recently falling to near a 52-week low, reflecting a potential area of ​​interest for value investors.

The financials paint a challenging picture, with the company not being profitable for the past twelve months and analysts expecting both a decline in sales and a decline in net income this year. The InvestingPro Tips it also points out that Inmune Bio is a niche player in its industry and has more cash than debt, which could be a stabilizing factor for the company’s balance sheet.

Despite the recent decline in the share price, with a return of -9.0% over the past week and -50.63% over the past six months, CFO’s investment suggests a belief in the company’s resilience and future prospects. Moreover, the company’s liquid assets exceed its short-term liabilities, which can provide some cushion against market headwinds.

For investors looking for more in-depth information, there are additional InvestingPro Tips available on Inmune Bio, Inc. These tips look at company valuation multiples, trading patterns and analyst expectations, all of which can be found at InvestingPro.

This article was generated with support from AI and reviewed by an editor. For more information, see T&C.